Conferences

Stay informed about upcoming pharma conferences, symposiums, and events. Discover opportunities to connect with industry experts, thought leaders, and researchers. Stay updated about the latest scientific advancements, networking opportunities, and educational programs in the pharmaceutical field.

TAVR devices equal surgery in long-term trials | Pharmtales

Medtronic, Edwards’ TAVR devices match surgery in long-term studies

Anika Sharma

At the Transcatheter Cardiovascular Therapeutics conference in San Francisco, both Medtronic and Edwards Lifesciences unveiled the latest results from ongoing ...

Amulet, Watchman tie in heart occluder study | Pharmtales

Abbott’s Amulet, Boston’s Watchman equal in heart occluder trial

Anika Sharma

The study, presented as a late-breaking feature at the Transcatheter Cardiovascular Therapeutics conference in San Francisco, assessed the safety and ...

Daiichi, AZ grow ADC portfolios post Enhertu | Pharmtales

Daiichi and AstraZeneca expand ADC pipelines after Enhertu triumph

Anika Sharma

At the European Society for Medical Oncology (ESMO) Congress, Daiichi Sankyo made a significant impact by striking a $4 billion ...

Cancer vaccine challenges for Moderna, BioNTech

Moderna, BioNTech face hurdles in cancer vaccine production after COVID success

Anika Sharma

Moderna and BioNTech, both navigating their post-COVID future while reimagining cancer treatments, have encountered manufacturing hurdles along their respective journeys. ...

Keytruda: Merck’s cancer drug shines and falters at ESMO

Keytruda: Merck’s breakthrough cancer drug with mixed results at ESMO

Anika Sharma

Merck & Co. made significant strides at this year’s European Society for Medical Oncology (ESMO) congress, presenting a series of ...

BioNTech’s CAR-T/CARVac Combo: Potent but Toxic (ESMO 2023)

BioNTech’s CAR-T/CARVac Combo Shows High Response Rates in Solid Tumors, But Also Higher Toxicity (ESMO 2023)

Anika Sharma

ESMO 2023: LBA35 BioNTech’s innovative manufacturing process for CAR-T therapy, BNT211, has shown promising results in treating solid tumors. While ...

Dato-DXd’s Mixed Results in Lung Cancer Trial (ESMO 2023)

Dato-DXd Shows Efficacy in Lung Cancer, But Safety Issues Remain (ESMO 2023)

Anika Sharma

ESMO 2023: LBA12 During the Presidential Symposium at the ESMO Congress 2023 in Madrid, a study revealed that datopotamab deruxtecan, ...

Pluvicto’s Hot-and-Cold Results in Prostate Cancer (ESMO 2023)

Pluvicto Improves Survival in Earlier Prostate Cancer, But Faces Regulatory Hurdles (ESMO 2023)

Anika Sharma

ESMO 2023: LBA13 Novartis is eagerly advancing its radiotherapy drug, Pluvicto, with aspirations of its potential in earlier prostate cancer ...

Ambrx’s ARX517 Impresses in Prostate Cancer Trial (ESMO 2023)

Ambrx’s ARX517 Shows Promising Efficacy and Safety in Advanced Prostate Cancer (ESMO 2023)

Anika Sharma

ESMO 2023: 1804P As of the data cutoff date in September 2023, the results from the study show that increasing ...

Merus’ Zeno Improves Outcomes in NRG1+ Cancers (ESMO 2023)

Merus’ Zeno Shows Higher Response Rates in NRG1+ Pancreatic and Lung Cancers (ESMO 2023)

Anika Sharma

ESMO 2023: 1618P Currently, Ipsen’s Onivyde is the standard of care, but it offers only a 7% chance of response ...

Imfinzi-Lynparza Beats Chemo in Endometrial Cancer (ESMO 2023)

Imfinzi and Lynparza Combo Improves Survival in Endometrial Cancer Trial (ESMO 2023)

Anika Sharma

ESMO 2023: LBA41 AstraZeneca is exploring a potentially powerful approach in the fight against endometrial cancer, suggesting that combining their ...

Cabometyx Halts Trial Early in Neuroendocrine Tumors (ESMO 2023)

Cabometyx Shows Dramatic Benefits in Advanced Neuroendocrine Tumors (ESMO 2023)

Anika Sharma

ESMO 2023: LBA53 Exelixis made headlines last month when its Cabometyx exceeded expectations in the treatment of neuroendocrine tumors (NETs), ...

Padcev-Keytruda Beats Chemo in Bladder Cancer (ESMO 2023)

Padcev-Keytruda Combo Doubles Survival in First-Line Bladder Cancer Trial (ESMO 2023)

Anika Sharma

ESMO 2023: LBA6 Exciting results from the EV-302 phase 3 trial suggest that the partnership between Seagen and Astellas’ antibody-drug ...

Opdivo vs Chemo vs Keytruda-Padcev in Bladder Cancer (ESMO 2023)

Opdivo Beats Chemo in First-Line Bladder Cancer, But Keytruda-Padcev Combo Looms Large (ESMO 2023)

Anika Sharma

ESMO 2023: LBA7 Bladder cancer has presented a unique challenge for immunotherapies, with Bristol Myers Squibb’s Opdivo making strides, but ...

Lumakras Boosts PFS in KRAS G12C-Mutated CRC (ESMO 2023)

Lumakras-Vectibix combo outperforms standard therapy in KRAS G12C-mutated colorectal cancer (ESMO 2023)

Anika Sharma

ESMO 2023: LBA10 Nevertheless, a shadow has been cast over the KRAS inhibitor due to recent criticisms by FDA advisors. ...

Retevmo Beats Keytruda + Chemo in RET+ NSCLC

Lilly Unveils Exciting Phase III Showdown: Retevmo vs. Keytruda & Chemotherapy in RET Fusion-Positive NSCLC

Anika Sharma

ESMO 2023: LBA4 RET fusion is found in about 1-2% of patients with non-small cell lung cancer. Retevmo, a highly ...

Alecensa Lowers Recurrence and Death in ALK+ NSCLC

Phase III ALINA study shows Alecensa’s superior disease-free survival benefit in early-stage lung cancer patients

Anika Sharma

ESMO 2023: LBA2 About 4-5% of NSCLC cases are identified with ALK rearrangements. In 2015, Alecensa (alectinib) received accelerated approval ...

Garsorasib + Cetuximab Active in KRAS G12C-Mutated CRC

A novel combination therapy of garsorasib and cetuximab for KRAS G12C mutated colorectal cancer patients

Anika Sharma

D‐1553 is a small-molecule inhibitor designed to selectively target KRAS G12C and is currently undergoing Phase II clinical trials. It ...

Combination of Osimertinib and Chemotherapy Enhances Brain Control in Advanced EGFR-Mutated Lung Cancer: Results from FLAURA2 Trial

Combination of Osimertinib and Chemotherapy Enhances Brain Control in Advanced EGFR-Mutated Lung Cancer: Results from FLAURA2 Trial

Anika Sharma

ESMO: LBA68 EGFR mutations are found in 10%-15% of non-small cell lung cancer (NSCLC) cases among European and Caucasian populations. ...

Imfinzi + Chemo Improves pCR in Gastric and GEJ Cancers (ESMO 2023)

Positive Interim Results from Global Phase III MATTERHORN Study: Imfinzi plus FLOT Demonstrates Clinically Meaningful Improvement in Key Secondary Endpoint (ESMO 2023)

Anika Sharma

ESMO 2023: LBA73 The results of a MATTERHORN trial was presented in ESMO 2023. The trial tested the effect of ...

Tarlatamab Improves Survival in Advanced SCLC (ESMO 2023)

Phase II DeLLphi-301 Study Reveals Impressive Antitumor Activity of Amgen’s First-in-Class Bispecific Antibody Tarlatamab (ESMO 2023)

Anika Sharma

ESMO 2023: LBA92 Most SCLC patients are diagnosed with cancer that has already spread beyond the lungs, and their average ...

Krazati + Keytruda Slows Down KRASG12C-Mutated NSCLC (ESMO 2023)

Promising Outcomes and Safety Profile of Krazati Combined with Pembrolizumab in Treatment-Naïve, Advanced NSCLC Patients with KRASG12C Mutation: Insights from the Phase II/III KRYSTAL-7 Study (ESMO 2023)

Anika Sharma

ESMO 2023: LBA65 NSCLC with KRAS mutations is a difficult market with few treatment options and many unmet needs. Krazati ...

Keytruda + Chemo Boosts Survival in Resectable NSCLC (ESMO 2023)

KEYNOTE-671 Trial: Keytruda Sets New Standards in the Perioperative Treatment Landscape (ESMO 2023)

Anika Sharma

ESMO 2023: LBA56 Neoadjuvant NSCLC is a challenging market with few treatment options and many unmet needs. Merck’s Keytruda is ...

ESMO 2023: Keytruda + Chemo Boosts pCR in ER+/HER2– Breast Cancer

Keytruda’s Success in KEYNOTE-756 Trial Ushers in a New Era for Early-Stage High-Risk ER+/HER2– Breast Cancer Treatment (ESMO 2023)

Anika Sharma

ESMO 2023: LBA21 Keytruda (pembrolizumab) is a highly specific, human-made antibody that targets the PD-1 pathway and prevents cancer cells ...

ESMO 2023

Rybrevant Redefines First-Line Care for Patients with EGFR Exon 20 Insertion Mutation (ESMO 2023)

Anika Sharma

ESMO 2023: LBA5 Targeted therapies have revolutionized the treatment of EGFR-mutant NSCLC in the last 20 years. However, EGFR exon ...

ESMO 2023: Opdivo + Chemo Boosts Survival in Resectable NSCLC

ESMO 2023: Bristol Myers Squibb’s Opdivo Plus Chemotherapy Improves Survival in Resectable NSCLC: CheckMate -816 Trial

Anika Sharma

ESMO 2023: Abstract ID 1261O Treating early-stage NSCLC presents numerous obstacles, given the restricted therapeutic alternatives available. In this landscape, ...

Conference, ESMO 2023, Keytruda, Breast Cancer, LBA18, KEYNOTE-522

How Keytruda Improved Survival Outcomes for Early-Stage TNBC Patients: KEYNOTE-522 Trial

Anika Sharma

ESMO 2023: LBA18 Underpinning this approval is the seminal KEYNOTE-522 trial, a Phase III study that diverges from pre-2021 tactics ...

ESMO 2023: Jemperli outperforms Keytruda in lung cancer trial

ESMO 2023: GSK’s Jemperli beats Merck’s Keytruda in lung cancer survival trial

Anika Sharma

In a groundbreaking clinical trial, GSK has achieved remarkable patient survival results with its PD-1 inhibitor, Jemperli, when compared to ...

IASLC WCLC 2023 Conference - Tagrisso, a targeted therapy, combined with chemotherapy, extended the median progression-free survival by nearly 9 months in patients with EGFR-mutated advanced lung cancer, according to the FLAURA2 Phase III trial.

Tagrisso-chemo combo delays EGFR NSCLC progression by 9 months in first-line (IASLC WCLC 2023 Conference)

Anika Sharma

Against the formidable challenge of non-small cell lung cancer (NSCLC), AstraZeneca’s Tagrisso (osimertinib), when partnered with chemotherapy, has unveiled remarkable ...

IASLC WCLC 2023 Conference - Fasenra, a biologic medicine, met the primary endpoint of inducing remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare and severe inflammatory disease.

Fasenra, a new treatment for EGPA, achieved remission in Phase III trial (IASLC WCLC 2023 Conference)

Anika Sharma

The MANDARA Phase III trial has shed new light on the effectiveness of AstraZeneca’s Fasenra (benralizumab). Unveiling favorable high-tier outcomes, ...

123 Next